series-c-plus
Stage
2
Investors
About
Xspray Pharma develops improved amorphous formulations of marketed protein kinase inhibitor drugs for oncology, using patented spray-drying technology to create formulations that can enter the market after original drug patents expire while retaining advantages over generic crystalline versions.
Explore Xspray Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.